MigVax is developing an oral subunit vaccine for COVID-19.

The VP of R&D will oversee and supervise all of the scientific activities of MigVax. This executive will be responsible for the:

• Technology transfer, including collaborative work with MIGAL's scientists and labs
• Support up scaling manufacturing including the bridging between MIGAL’s scientists and manufacturing facilities
• Support pre-clinical and clinical development of the vaccine. These may include support of collaborations worldwide, conducting science and bench work outside of academia to support pre-clin and clin development
• Potential integration of new technologies and supporting Company innovation, within the company, or through collaborations.

The VP of R&D will be responsible for recruiting and building the required teams as well as direct the R&D efforts of the Company.

The VP of R&D will be responsible for budgets, timelines and reporting to management and Board.